[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367755-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367755-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","acute-promyelocytic-leukemia-in-a-patient-with-sickle-cell-hemoglobin-d-disease-a-case-report","Acute Promyelocytic Leukemia in a Patient With Sickle Cell Hemoglobin D Disease - A Case Report","","Myeloid neoplasms may develop in patients with sickle cell disease, yet the precise biologic link remains unclear. Chronic inflammation from sickling crises may promote cytogenetic aberrations that increase risk, and hydroxyurea has been suggested as an additional factor in some reported cases of myeloid malignancies. To investigate this association, the case report describes acute promyelocytic leukemia in a patient with sickle cell hemoglobin D disease who had never received hydroxyurea.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/acute-promyelocytic-leukemia-in-a-patient-with-sickle-cell-hemoglobin-d-disease-a-case-report/367755/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/acute-promyelocytic-leukemia-in-a-patient-with-sickle-cell-hemoglobin-d-disease-a-case-report/367755.png","ImageObject",300,407,{"name":42,"@type":43},"Mabel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical link is proposed between sickle cell disease and myeloid neoplasms?","Question",{"text":63,"@type":64},"The article proposes that chronic inflammation associated with sickling crises may lead to cytogenetic aberrations, increasing the risk of myeloid neoplasms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is hydroxyurea mentioned in relation to myeloid malignancies?",{"text":68,"@type":64},"Hydroxyurea is described as reducing sickling frequency via increasing fetal hemoglobin, but some reported cases have associated long-term use with myeloid malignancies or myelodysplastic syndromes.",{"name":70,"@type":61,"acceptedAnswer":71},"What is notable about the reported case’s exposure to hydroxyurea?",{"text":72,"@type":64},"The case describes acute promyelocytic leukemia in sickle cell hemoglobin D disease without any prior exposure to hydroxyurea.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367755,1791068393,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Review began 06/29/2025  \nReview ended 07/07/2025  \nPublished 07/08/2025  \n© Copyright 2025  \nBokhary et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CCBY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.87513  \nOpen Access Case Report  \nAcute Promyelocytic Leukemia in a Patient With Sickle Cell Hemoglobin D Disease: A Case Report  \nMahmoud Bokhary 1, Esra Turak 2, Rehab Ibrahim 2, Aly Rashed 2 , Mohamed Abdelhadi 2, Cigdem Ozturk 2, Shruti Sudha 2, Leylagul Kaynar 2, Elias Fadel 2  \n1. Hematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GBR 2. Hematology, King Hamad University Hospital, Al Muharraq, BHR  \nCorresponding author: Mahmoud Bokhary, [mahmoud.bokhary@gmail.com](mahmoud.bokhary@gmail.com)  \nAbstract  \nMyeloid neoplasms can occur in patients with sickle cell disease; however, the underlying connection between the two remains unclear. These neoplasms, along with other cancers such as female breast cancer and male genital cancer, may arise de novo or secondarily due to chronic inflammation associated with sickling crises. This chronic inflammation, and its downstream effects, may lead to cytogenetic aberrations that increase the risk of developing myeloid neoplasms. Another potential risk factor is hydroxyurea, a medication commonly used to reduce the frequency of sickling crises, with some reported cases of associated myeloid malignancies. To explore this possible link, we present a case of acute promyelocytic leukemia in a patient with sickle cell hemoglobin D disease who had never received hydroxyurea.  \nCategories: Hematology  \nKeywords: acute promyelocytic leukemia (apml), deep vein thrombosis (dvt), d-punjab, hydroxycarbamide, sickle cell disease (scd)  \nIntroduction  \nSickle cell disease is an inherited autosomal recessive hemoglobin disorder caused by a point mutation at the sixth codon of the β-globin gene, leading to the substitution of hydrophilic glutamic acid with hydrophobic valine. This abnormal hemoglobin is poorly soluble in its deoxygenated state [1] . The resulting pathophysiology gives rise to a range of clinical manifestations, including vaso-occlusive crises, hemolytic anemia, acute chest syndrome, and bone necrosis, complications that may lead to lifelong disability or even death [2] . Individuals who are homozygous for hemoglobin S often exhibit severe clinical symptoms, whereas heterozygous carriers typically present with minimal or no symptoms [3] .  \nVariant sickle cell syndromes arise when hemoglobin S is inherited alongside another specific β-globin gene mutation, such as those involving the alpha, beta, or gamma globin chains. This results in compound heterozygous hemoglobinopathies that may present with clinical features similar to, or distinct from, homozygous hemoglobin S disease. One such rare variant is sickle cell hemoglobin D disease [4] . The most well-known hemoglobin D variant is HbD Los Angeles (also known as HbD Punjab), which results from a  \nglutamic acid to glutamine substitution at codon 121 of the β-globin gene (β121 Glu→Gln) [5] .  \nAlthough individuals with heterozygous mutations may be asymptomatic, those with compound  \nheterozygosity for HbS and HbD (HbSD disease) can experience severe symptoms resembling those of homozygous HbS disease. This is due to the polymerization of HbS under deoxygenated conditions [5,6] .  \nHbD Los Angeles shares electrophoretic mobility with HbS under alkaline conditions but can be  \ndifferentiated by acidic electrophoresis or isoelectric focusing. Common clinical presentations include hemolytic anemia with splenomegaly, vaso-occlusive crises, and acute chest syndrome. Peripheral blood (PB) smears often reveal marked anisocytosis, poikilocytosis, target cells, and sickled red blood cells (RBCs)  \n[7] .  \nHydroxyurea is a well-established supporti","cbCaisZHdM5tF0zu","https://ap.wps.com/l/cbCaisZHdM5tF0zu","pdf",1885649,"English","# Abstract\n# Introduction\n# Case Presentation\n## Initial Laboratory Investigations","[{\"question\":\"What clinical link is proposed between sickle cell disease and myeloid neoplasms?\",\"answer\":\"The article proposes that chronic inflammation associated with sickling crises may lead to cytogenetic aberrations, increasing the risk of myeloid neoplasms.\"},{\"question\":\"Why is hydroxyurea mentioned in relation to myeloid malignancies?\",\"answer\":\"Hydroxyurea is described as reducing sickling frequency via increasing fetal hemoglobin, but some reported cases have associated long-term use with myeloid malignancies or myelodysplastic syndromes.\"},{\"question\":\"What is notable about the reported case’s exposure to hydroxyurea?\",\"answer\":\"The case describes acute promyelocytic leukemia in sickle cell hemoglobin D disease without any prior exposure to hydroxyurea.\"}]","Acute Promyelocytic Leukemia in a Patient With Sickle Cell Hemoglobin D Disease - A Case Report | PDF",1790172397,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0974c907e478ac7eed09d1f11734c387.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3bda1ca0d856fbc89aca60056c7222e.webp",982,1389,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/984868cb21a002cd858da7395792a2dd.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f1f147cf70a4e9c37d453056fd3e02a.webp",980,1386]